Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T
Cancer. 1987 Feb 15;59(4):748-54. doi: 10.1002/1097-0142(19870215)59:4<748::aid-cncr2820590414>3.0.co;2-e.
Tissue factor activity (TFA) of 10(8) leukemia cells was measured in 82 patients with acute nonlymphoid leukemia by the clotting method. The TFA bore a significant correlation to the development of disseminated intravascular coagulation (DIC) in these cases. Mean TFA value with standard deviation (SD) was 8.3 +/- 6.3 U in 48 cases with DIC, which was significantly higher than 0.3 +/- 4.2 U in 34 cases without DIC. Whereas Mean TFA in non-M3 was 0.9 +/- 6.3 U which was significantly lower than 37.2 +/- 2.3 U in M3, some non-M3 showed TFA as high as M3 and were complicated by DIC. In heparin treatment, dosage of heparin could not be controlled by either APTT or AcCT but was controlled by the extent of TFA of leukemia cells. Retrospective analysis of clinical features revealed that 97000X + 9000 units/day (X = logarithm value of TFA) of heparin is an adequate dosage for the successful treatment of DIC when TFA of leukemia cells is 0.8 U or more.
采用凝血法对82例急性非淋巴细胞白血病患者的10⁸个白血病细胞的组织因子活性(TFA)进行了检测。在这些病例中,TFA与弥散性血管内凝血(DIC)的发生显著相关。48例发生DIC患者的平均TFA值及标准差(SD)为8.3±6.3 U,显著高于34例未发生DIC患者的0.3±4.2 U。非M3型患者的平均TFA为0.9±6.3 U,显著低于M3型患者的37.2±2.3 U,部分非M3型患者的TFA与M3型患者一样高,并伴有DIC。在肝素治疗中,肝素剂量不能通过活化部分凝血活酶时间(APTT)或活化凝血时间(AcCT)来控制,而是由白血病细胞的TFA水平来控制。临床特征的回顾性分析显示,当白血病细胞的TFA为0.8 U或更高时,97000X + 9000单位/天(X = TFA的对数值)的肝素剂量是成功治疗DIC的合适剂量。